mo:re, a life science startup from Hamburg University of Technology (TUHH), has received seed funding of 2.3 million euros to accelerate the commercialization of its innovative laboratory platform. The investment was led by High-Tech Gründerfonds (HTGF), with participation from Innovationsstarter Fonds Hamburg (IFH) and international investors such as Gilson Inc, NEDGEX, Nidobirds Ventures and private investors R&R Medical and Martin Blüggel.
The platform developed by mo:re automates the planning, cultivation and analysis of complex 3D cell culture models, setting new standards for animal-free drug development. The aim is to establish organoids as a standard laboratory technique and offer researchers a reproducible, scalable and standardized environment. The start-up is thus responding to current developments, such as the new FDA guidelines, which pave the way for the replacement of animal testing with relevant organoid models.
“With this funding, we want to expand our market presence and further develop our platform to unlock the full potential of animal-free drug research,” explains Lukas Gaats, CEO of mo:re.
The mo:re platform combines automation and software to optimize the entire cell culture workflow – from sample preparation to analysis. This ensures greater reproducibility and quality, while at the same time speeding up the research process.
“The mo:re team is well on the way to providing researchers worldwide with an easily accessible, standardized method for performing 3D cell cultures,” emphasizes Dr. Christian Kannemeier, Senior Investment Manager at HTGF.
Through its close ties with the TUHH and the support of renowned investors, mo:re aims to play a decisive role in shaping the future of drug research without animal testing.
Further information can be found at www.more.science
Hamburg University of Technology is part of the Startup Port network.
